Recent RPTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 12:01:39 PM
- Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions • Business Wire • 01/09/2025 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2024 09:28:58 PM
- Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial • Business Wire • 12/12/2024 09:20:00 PM
- Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial • Business Wire • 12/10/2024 09:05:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 10:05:19 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 02:42:55 PM
- Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib • Business Wire • 11/12/2024 12:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2024 01:33:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 12:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 12:10:07 PM
- Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results • Business Wire • 11/07/2024 12:05:00 PM
- Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial • Business Wire • 10/23/2024 10:05:00 AM
- Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor • Business Wire • 10/14/2024 11:05:00 AM
- Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting • Business Wire • 09/30/2024 08:05:00 PM
- Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers • Business Wire • 09/23/2024 11:05:00 AM
- Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 • Business Wire • 09/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 08:15:31 PM
- Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio • Business Wire • 08/28/2024 08:05:00 PM
- Repare Therapeutics to Participate in Two Upcoming Investor Conferences • Business Wire • 08/27/2024 11:05:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/20/2024 04:15:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 01:06:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/06/2024 08:41:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:20:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:11:38 PM
FEATURED ImagineAR's FameDays Secures $10 Million Contract to Develop 25,000 Sq. Ft. Immersive Entertainment Center at a Niagara Falls Hotel in Canada • Feb 25, 2025 8:00 AM
Consumer Automotive Finance, Inc. Finalizes Agreement to Retire 246 Million Common Shares: Strategic Move Signals Robust Commitment to Shareholder Value Enhancement • CAFI • Feb 25, 2025 9:00 AM
VAYK To Offer Service Solution Capitalizing on $11.1 Billion Airbnb Revenue • VAYK • Feb 24, 2025 9:00 AM
ConnectM Announces $11.3M Q1 '25 Preliminary Revenue Guidance, a 100% YoY Surge • CNTM • Feb 24, 2025 9:00 AM
ConnectM Announces Q1 2025 Preliminary Revenue Guidance of $11.3M, Representing a 100% Year-Over-Year Surge • CNTM • Feb 21, 2025 7:17 AM
Consumer Automotive Finance Inc. (CAFI) Completes Final Steps with FINRA, Expects Name and Ticker Change to Fifty 1 Labs, Inc. (FITY) Within 30 Days • CAFI • Feb 20, 2025 9:00 AM